Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

Five Indian-origin women and an Indian woman have been named in Fortune’s 2025 Most Powerful Women list. The list is topped ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...

Reshma Kewalramani, Bela Bajaria, Revathi Advaithi and Meena Lakdawala Flynn among women at the top of the global business ...

Princeton University awarded honorary degrees to Omar M. Yaghi, Daniel Chee Tsui, Nancy Weiss Malkiel, Joshua ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals, a biotech giant best known for its cystic fibrosis drugs, took a stumble after missing Q1 2025 ...

These findings reinforce ETI therapy as the gold standard therapy in the CF treatment landscape. Since its Food and Drug Administration (FDA) approval in 2019 and subsequent EMA approval in 2020, ...

Vertex Pharma has chosen the three-drug combination it intends to submit for approval later this year for cystic fibrosis, in a bid to add another product to its stable. The US company has plumped ...